News & Updates

Pazopanib plus chemo improves response but not survival in advanced ovarian cancer

08 Jun 2023

Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).

Pazopanib plus chemo improves response but not survival in advanced ovarian cancer

08 Jun 2023

First-line cemiplimab improves survival in unresectable NSCLC

08 Jun 2023 by

First-line treatment with cemiplimab, either as monotherapy or in combination with platinum-based chemotherapy, provides clinical benefits to patients with unresectable locally advanced nonsmall cell lung cancer (NSCLC) who are not candidates for definitive concurrent chemoradiation, as shown by long-term follow-up data from EMPOWER-Lung studies.

First-line cemiplimab improves survival in unresectable NSCLC

08 Jun 2023

Psychedelic drugs show promise for anxiety, depression

08 Jun 2023

Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.

Psychedelic drugs show promise for anxiety, depression

08 Jun 2023

Obesity raises all-cause, cardiovascular death risks in asthma

08 Jun 2023

For adults with asthma, obesity but not overweight poses an increased risk of all-cause and cardiovascular mortality, according to a study.

Obesity raises all-cause, cardiovascular death risks in asthma

08 Jun 2023

Coeliac disease prevalent in patients with liver disorder

07 Jun 2023

Coeliac disease (CeD) appears to be common in patients with cryptogenic cirrhosis or cryptogenic hypertransaminasaemia, suggests a study, noting that these individuals must be considered high-risk groups for CeD.

Coeliac disease prevalent in patients with liver disorder

07 Jun 2023

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?

07 Jun 2023 by

Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?

07 Jun 2023

7-day modified fasting therapy improves health, body weight of hospitalized patients

07 Jun 2023

Modified fasting therapy for 7 days is both safe and effective for improving physical health, body weight-related indicators, body composition, and relevant cardiovascular risk factors in hospitalized patients, results of a recent study have shown.

7-day modified fasting therapy improves health, body weight of hospitalized patients

07 Jun 2023

Germline genetic testing registers low numbers

07 Jun 2023

The adoption rate of germline genetic testing among individuals diagnosed with cancer in some states in the US over a period of 6 years remains subpar, with only 6.8 percent undergoing testing, as reported in a study.

Germline genetic testing registers low numbers

07 Jun 2023

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

07 Jun 2023 by

A retrospective observational cohort study finds that patients with relapsing-remitting multiple sclerosis (RRMS) who switched from natalizumab to ocrelizumab had lower annual relapse and discontinuation rates and longer time to first relapse than those who switched to dimethyl fumarate or fingolimod.

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

07 Jun 2023

T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality

07 Jun 2023 by

A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.

T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality

07 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

Pazopanib plus chemo improves response but not survival in advanced ovarian cancer

Pazopanib plus chemo improves response but not survival in advanced ovarian cancer

First-line cemiplimab improves survival in unresectable NSCLC

First-line cemiplimab improves survival in unresectable NSCLC

Psychedelic drugs show promise for anxiety, depression

Psychedelic drugs show promise for anxiety, depression

Obesity raises all-cause, cardiovascular death risks in asthma

Obesity raises all-cause, cardiovascular death risks in asthma

Coeliac disease prevalent in patients with liver disorder

Coeliac disease prevalent in patients with liver disorder

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?

7-day modified fasting therapy improves health, body weight of hospitalized patients

7-day modified fasting therapy improves health, body weight of hospitalized patients

Germline genetic testing registers low numbers

Germline genetic testing registers low numbers

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality

T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality